Floatz logo

[68Ga] B7H3 Affibody-BCH

B7H3

Peking University Cancer Hospital & InstituteEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the B7H3 cohort.

Asset / SponsorPhaseRating
[64Cu]Cu-AKY-2519
Aktis Oncology, Inc.
Phase 1CC
[225Ac]Ac-AKY-2519
Aktis Oncology, Inc.
Phase 1CC

Same molecule, other indications

[68Ga] B7H3 Affibody-BCH is also rated in:

CD276 AffibodyDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →